On October 7, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, reported that it has been informed by the European Patent Office that the examining division intends to grant the company a European Patent for the Company’s application titled "A System and Method for High Throughput Screening of Cancer Cells (Press release, Cannabics Pharmaceuticals, OCT 27, 2020, View Source [SID1234570699])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Drug Sensitivity Heatmap of Multiple Cannabinoids and Cancer Cells

This patent application relates to the company’s CANNABICS CDx companion diagnostic drug sensitivity test, whereby a patient’s biopsy is screened to match the optimal cannabinoid combination available using the company’s high throughput screening of cancer cells proprietary technology.

Outside the European territory, this patent is also currently being reviewed in other territories including the US and Canada. The decision of the European examiner is significant in that it could also accelerate the review process in other territories who offer a Patent Prosecution Highway such as Canada, India, Mexico and Brazil.

Gabriel Yariv, Cannabics Pharmaceuticals’ President and COO said: "This patent exemplifies our pioneering vision to bring Cannabinoid-based therapies and treatments to cancer patients worldwide and will strengthen our position as we concentrate on penetrating the European market".

Dr. Eyal Ballan, Cannabics Pharmaceuticals’ CTO, said:" As pioneers in Cannabinoid-based Cancer diagnostics, we have always believed in the novelty and uniqueness of our vision to personalize cannabinoid treatments. The intention of the European examiner to grant our patent is certainly a positive vindication for our efforts".

On October 27, 2020 Bayer reported that Nubeqa has scored backing from the UK’s National Institute for Health and Care Excellence (NICE) for treating non-metastatic castration-resistant prostate cancer (nmCRPC) (Press release, PharmaTimes, OCT 27, 2020, View Source [SID1234569473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nubeqa (darolutamide) has been authorised for use alongside androgen deprivation therapy (ADT). According to Bayer, it is the first treatment NICE has recommended in this indication.

The NICE recommendation is based on results from the phase III ARAMIS trial, which evaluated the efficacy and safety of Nubeqa plus ADT in nmCRPC patients.

In this trial, Nubeqa plus ADT demonstrated a statistically significant improvement in the primary efficacy endpoint of metastasis-free survival (MFS), with a median 40.4 months compared to 18.4 months for placebo plus ADT.

The final overall survival (OS) data – a secondary endpoint in the ARAMIS trial – demonstrated a significant improvement in OS compared to placebo plus ADT, with a 31% reduction in the risk of death.

"Bayer welcomes NICE’s positive recommendation for Nubeqa, ensuring men with nmCRPC who are at high risk of developing metastatic disease have access to therapeutic options that delay disease progression, whilst improving overall survival, when compared to placebo and ADT alone," said Melissa Rowe, director of medical affairs for specialty medicine at Bayer UK.

"Bayer is dedicated to research that aims to address the unmet need in the way cancer is treated, with a particular focus on prostate cancer," she added.

Prostate cancer is the most common cancer in men in the UK, with over 48,000 new cases each year on average.

Approximately a third of men with nmCRPC develop metastases within two years, highlighting the need for treatment which delay the development of metastases in this patient population.

On October 27, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reported an increase in its financial guidance for the financial year 2020 after preliminary completion of the latest evaluation of MorphoSys’ financial performance (Press release, MorphoSys, OCT 27, 2020, View Source [SID1234569206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the preliminary unaudited consolidated results for the first nine months 2020, MorphoSys now expects Group revenues in the range of €317 to €327 million (previously: €280 to €290 million) and an EBIT in the range of €10 to €20 million (previously: €-15 to €+5 million). R&D expenses are expected to remain unchanged in the range of €130 to €140 million.

The updated guidance reflects higher revenues from partnerships and collaborations and Tremfya royalties are expected to be at the upper end of guidance. In addition, it now also includes revenues from product sales of Monjuvi following its approval and subsequent launch in the U.S.

In the first nine months of 2020, MorphoSys recorded Group revenues of €291.7 million and an EBIT of €101.8 million. Further details will be published in the Company’s Q3 report on November 11, 2020.

On October 27, 2020 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report business results for the third quarter 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020 (Press release, Supernus, OCT 27, 2020, View Source;2020.htm [SID1234569196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and CEO and the executive management team will host a conference call to present the third quarter 2020 business and financial results on Wednesday, November 4, 2020 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.
A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
Conference dial-in: (877) 288-1043 International dial-in: (970) 315-0267 Conference ID: 1882244 Conference Call Name: Supernus Pharmaceuticals Third Quarter 2020 Earnings Conference Call

Following the live call, a replay will be available on the Company’s website under the ‘Investor Relations’ section. The webcast will be available on the Company’s website for 60 days following the live call.

On October 27, 2020 TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, reported the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II). Committed capital totals US$478 million which was raised from high profile international investors, including Eli Lilly and Company, other strategic investors, pension funds, endowments, foundations, fund-of-funds, wealth managers and large US banks as well as multi and single family offices from the Americas, Europe and South Korea (Press release, TVM Life Science Management, OCT 27, 2020, View Source [SID1234569175]). The geographical focus for the Fund’s investment activity is on North-America and Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TVM LSI II was substantially oversubscribed. The Fund already sold its first investment in February 2020.

TVM LSI II will maintain TVM’s focus on investing in assets that provide a visible and attractive exit strategy from the outset with the goal of maximizing returns and providing early and significant liquidity for its investors. About 50-60% of the Fund’s capital is intended to be invested in "Project Focused Companies" ("PFCs") which are majority-owned by the Fund and set up for the development of early-stage drug candidates in a capital and time efficient manner. The remaining capital will be invested in late clinical stage biopharmaceutical companies as well as commercial stage medical device and diagnostic companies. The proven focus of TVM LSI II continues on building a portfolio of differentiated first-in-class and best-in-class assets that are diversified by indication and stage of development.

Dr. Luc Marengere, Managing Partner of TVM Capital Life Science commented: "We are thrilled by the strong support of existing and new investors in TVM LSI II. TVM LSI II is the largest fund raised by TVM since inception. In addition, we are grateful for the pivotal role in raising TVM LSI II in the Americas and Europe by New York based OCP and Founder Joelle Wyser-Pratte."

Stefan Fischer, Managing Partner (Finance) stated: "We are confident that TVM LSI II will not only continue the TVM success story for our investors but will also enable the financing of the development of new and differentiated treatment options for patients with significant unmet medical needs."

"The success of this fundraising effort is a strong validation of the innovative, capital-efficient investment strategy that we have implemented in 2012 together with Eli Lilly and Company. TVM LSI II intends to make investments in about 16 early-stage single asset PFCs and 10 late-stage companies with a focus on North America and Europe," wrote Dr. Hubert Birner, Managing Partner of TVM Capital Life Science based in Munich.

With the closing of TVM LSI II, Stefan Fischer was promoted to Managing Partner (Finance) and Dr. Sascha Berger was promoted to Partner.

In the past few months, the TVM investment team was complemented with the addition of Alexandra MacLean, MD and Alain Thibault, MD as Principals and, Dr. Valentina Agostina, Catello Somma and Philipp Lechner as Associates.